Mortgage-Style Payments For High-Cost Drugs Left On Cutting-Room Floor
NASEM's 'Making Medicines Affordable' report assembled a big package of recommendations (8), implementing actions (27), and findings (18), but the committee passed over one idea that might be important for curative treatments in the future.
You may also be interested in...
Second meeting of National Academies drug pricing committee was far-reaching discussion of several major themes, including PBM transparency, the political future for co-pay coupons and the next possible inflection point: the potential $1 million price tag for gene therapies.
Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.
Two outside groups aim to help CBER on gene therapy questions from ‘N of one’ to markers for hemophilia.